Zolbetuximab-Vyloy’s association with Astellas and its use in treatment

Zolbetuximab, trade name VYLOY, is a monoclonal antibody targeting Claudin 18.2 (CLDN18.2) developed by the Japanese pharmaceutical company Astellas Pharma Inc. The drug is designed to treat patients with CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric cancer and gastroesophageal junction adenocarcinoma.

CLDN18.2 is a tight junction protein highly expressed in gastric cancer cells. Zotuximab blocks the growth and spread of tumor cells by specifically binding to CLDN18.2. Astellas, as the world's leading biopharmaceutical company, also has deep accumulation and rich experience in the research and development of antibody drugs. Although zotuximab is not directly developed by Astellas, certain targeted therapies in its product line have potential synergies with zotuximab, which provides clinicians with more treatment options.

Clinical trials have shown that zotuximab combined with chemotherapy can significantly extend the progression-free survival (PFS) and overall survival (OS) of patients. In the SPOTLIGHT study, the median PFS and OS in the zotuximab group were 10.61 months and 18.23 months, respectively, compared with 8.67 months and 15.54 months in the placebo group. The GLOW study also showed similar results. The median PFS and OS of the zotuximab group were 8.21 months and 14.39 months, both of which were better than the placebo group.

During the specific treatment process, doctors will decide whether to use zotuximab or its combination therapy with Astellas products based on the patient's specific condition, molecular characteristics of the tumor, and existing treatment options. Especially in patients with gastric cancer, zotuximab can target specific biomarkers, such asCLDN18.2, a feature that gives it an advantage in selecting a suitable patient group. The strategy of combining drugs can improve the efficacy to a certain extent while reducing the incidence of drug resistance.

Reference: https://medlineplus.gov/druginfo/meds/a624072.html